EGFR and non-small cell lung carcinoma: The prognosis of patients with EGFR‐ and ALK‐positive NSCLC has significantly improved following treatment with EGFR tyrosine kinase inhibitors (EGFR‐TKIs) and ALK–TKIs, respectively.